New Delhi, Nov 26
Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable access are the major barriers, according to a report on Tuesday.
Biologic therapy, also known as immunotherapy, is a type of treatment that uses substances derived from living organisms to treat disease.
The report by GlobalData, a data and analytics company, showed that the new Biologics target specific inflammatory pathways, shifting care from symptom control to potential remission.
Biologic treatments like dupilumab interleukin-4 receptor alpha and tezepelumab (anti-thymic stromal lymphopoietin (TSLP)) show potential for wider application. They also offer benefits to patients with various inflammatory profiles.
As per real-world evidence, these therapies have proved their efficacy across diverse patient profiles, including those with complex asthma cases.
However, the report cited barriers such as cost and accessibility. It stressed the urgent need for equitable healthcare solutions to ensure the widespread adoption of these transformative treatments.